---
layout: default
title: Fluocinolone Acetonide
parent: 僅模型預測 (L5)
nav_order: 360
evidence_level: L5
indication_count: 4
---

# Fluocinolone Acetonide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluocinolone Acetonide: From Topical Anti-Inflammatory Use to Lichen Planus Pigmentosus

## One-Sentence Summary

Fluocinolone acetonide is a halogenated topical corticosteroid classically used for inflammatory and pruritic skin conditions (and, in specialized ophthalmic implant form, for diabetic macular edema and non-infectious posterior uveitis). The TxGNN model predicts it may be effective for **Lichen Planus Pigmentosus**, but this prediction currently has **0 clinical trials** and **0 publications** in direct support — it is a pure knowledge-graph prediction with no confirmatory evidence yet.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Inflammatory and pruritic skin conditions (topical corticosteroid); drug is not currently marketed in Taiwan, so this is derived from pharmacological/clinical-use reference data rather than a TFDA label |
| Predicted New Indication | Lichen Planus Pigmentosus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not Marketed (未上市) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

The formal mechanism-of-action field for this drug is marked as a data gap. However, pharmacology reference data included in this evidence pack shows fluocinolone acetonide acts as a synthetic glucocorticoid receptor (NR3C1) agonist, the same target class shared by all clinically used topical/systemic corticosteroids. Its established clinical use is as an anti-inflammatory, anti-pruritic agent applied topically to skin, and in modified implant formulations for ocular inflammatory conditions (diabetic macular edema, non-infectious posterior uveitis).

Lichen planus pigmentosus is a pigmented variant within the lichen planus disease family, a lichenoid inflammatory dermatosis in which T-cell-mediated cytotoxic activity against basal keratinocytes plays a central role. Topical corticosteroids are already a mainstay treatment for classic lichen planus and its variants because they suppress T-cell activation and downstream inflammatory mediator release — the same pathway fluocinolone acetonide targets. This provides a plausible mechanistic rationale for TxGNN's prediction.

That said, this rationale is currently theoretical. Notably, this evidence pack contains **four** TxGNN-predicted lichen-planus-family indications for this drug (lichen planus pigmentosus, annular atrophic lichen planus, hypertrophic lichen planus, and lichen planus pemphigoides), all scored near 99.3–99.4%. Of these, only **lichen planus pemphigoides** (rank 4) has any literature support — 3 publications on topical corticosteroids (including fluocinonide, a related fluorinated corticosteroid) for oral vesiculoerosive/lichen planus-spectrum disease. This lends indirect, class-level support to the broader hypothesis that topical corticosteroids are relevant to lichen planus variants, but it is not direct evidence for lichen planus pigmentosus specifically, and the original MOA linkage remains unconfirmed by primary source data.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

*(Note: 3 publications exist for the related predicted indication "lichen planus pemphigoides" — see rationale above — but none map directly to lichen planus pigmentosus.)*

---

## Taiwan Market Information

This drug currently has no marketing authorizations registered in Taiwan (0 licenses; market status: 未上市 / Not Marketed).

---

## Safety Considerations

**Drug Interactions**: DDInter data lists 9 documented interacting agents, though none have a classified severity level (all reported as "Unknown"): Dexamethasone, Cetirizine, Citalopram, Valproic acid, Acetaminophen, Digoxin, Levothyroxine, Alendronic acid, Clonazepam. Clinical significance of these interactions has not been established from available data and requires further evaluation before use.

Key warnings and contraindications are not currently available for this drug — please refer to the package insert once available.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is a pure L5 model prediction for lichen planus pigmentosus with zero supporting clinical trials or literature, the drug is not marketed in Taiwan (no local safety/label data), and both TFDA warning/contraindication data (Blocking gap) and confirmed MOA data (High-severity gap) are missing — insufficient basis to advance past initial screening.

**To proceed, the following is needed:**
- TFDA label/insert data (or equivalent reference-market label) to establish warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism-of-action data via DrugBank API query (currently a High-severity data gap)
- Disease-specific case reports, case series, or trials evaluating corticosteroids (ideally fluocinolone acetonide specifically) in lichen planus pigmentosus
- Clarification of route compatibility — available formulations (topical/ophthalmic) versus routes required for treating lichen planus pigmentosus, which remains marked "pending"
- Severity/clinical-significance grading for the 9 unclassified drug interactions before any safety sign-off
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

